AstraZeneca PLC (AZN) said it would cut its U.S. sales force by about 24% by eliminating about 1,150 leadership and sales-representative positions, as the drug maker expands a years-long effort to pare staff and save costs.
The company said the reduction was additional to its ongoing restructuring program unveiled early last year, when it said it would cut thousands more jobs over coming years because of expectations for sliding profit and revenue-growth challenges. Wednesday's U.S. sales force cuts are also additional to previously announced efficiency plans in the company's U.S. business.
No comments:
Post a Comment